Aller au contenu principal
Accès ouvert déclaré 2025 article

Pharmacokinetics and Pharmacodynamics of neffy, Epinephrine Nasal Spray, in Pediatric Allergy Patients

18Citations signalées, ce qui n’est pas une note de qualité
8Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Epinephrine is the gold-standard treatment for severe allergic reactions, including anaphylaxis, and is typically administered via intramuscular injection. Despite epinephrine's well-documented safety and efficacy, patients may be hesitant to administer/receive injections, thereby increasing the risk of complications. neffy epinephrine nasal spray was developed to provide an additional option that may reduce dosing hesitancy. OBJECTIVE: This study was conducted to characterize neffy's pharmacokinetic and pharmacodynamic profiles in pediatric subjects, and to compare profiles between pediatric and adult subjects. METHODS: This was a phase 1, multicenter, single-dose, pharmacokinetic/pharmacodynamic study. Forty-two pediatric patients were dosed with 1 or 2 mg of neffy, based on weight. Pharmacokinetic and pharmacodynamic parameters were summarized with descriptive statistics and analyzed using a linear mixed effects model. RESULTS: In pediatric subjects, neffy 1 mg resulted in a slightly lower mean maximum concentrations relative to neffy 2 mg (651 vs 690 pg/mL), which were higher than the maximum concentrations in adult subjects (481 pg/mL). Although adult subjects demonstrated a marked postdose increase in systolic blood pressure, the systolic blood pressure increase observed in pediatric patients was significantly lower and was accompanied by minimal differences in diastolic blood pressure. The effect on heart rate was similar between both pediatric and adult subjects. CONCLUSIONS: In pediatric subjects, both the 1 and 2 mg doses of neffy resulted in mean maximum concentration values that are expected to be both safe and efficacious. Age-related differences in pharmacodynamic responses were noted; however, these differences are likely attributable to expected age-based differences in physiology.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Pharmacokinetics and Pharmacodynamics of neffy, Epinephrine Nasal Spray, in Pediatric Allergy Patients
Date Crossref
01/06/2025
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Food Allergy and Anaphylaxis ResearchDrug-Induced Adverse ReactionsRespiratory and Cough-Related Research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.